HB Wealth Management LLC bought a new stake in shares of Revvity, Inc. (NYSE:RVTY – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,908 shares of the company’s stock, valued at approximately $200,000.
Other large investors have also recently modified their holdings of the company. Nomura Asset Management Co. Ltd. bought a new position in Revvity in the 4th quarter valued at $3,593,000. BNP Paribas Financial Markets bought a new position in Revvity in the 4th quarter valued at $12,039,000. Principal Financial Group Inc. bought a new position in Revvity in the 4th quarter valued at $15,213,000. Russell Investments Group Ltd. bought a new position in Revvity in the 4th quarter valued at $10,291,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Revvity in the 4th quarter valued at $1,160,000. Institutional investors own 86.65% of the company’s stock.
Revvity Trading Up 0.3 %
Revvity stock opened at $122.54 on Friday. The stock has a 50-day moving average of $114.26 and a two-hundred day moving average of $108.93. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.27. Revvity, Inc. has a one year low of $79.50 and a one year high of $128.15. The stock has a market cap of $15.12 billion, a PE ratio of 101.27, a price-to-earnings-growth ratio of 2.97 and a beta of 1.05.
Revvity Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date of this dividend is Friday, October 18th. Revvity’s dividend payout ratio (DPR) is presently 23.14%.
Wall Street Analyst Weigh In
Several equities analysts have commented on RVTY shares. TD Cowen upped their price objective on Revvity from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Barclays increased their price target on Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 30th. JPMorgan Chase & Co. increased their price target on Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Jefferies Financial Group increased their price target on Revvity from $115.00 to $125.00 and gave the stock a “hold” rating in a research report on Monday, July 29th. Finally, Bank of America increased their price target on Revvity from $118.00 to $127.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $126.00.
View Our Latest Research Report on Revvity
Insider Buying and Selling at Revvity
In other Revvity news, insider Joel S. Goldberg sold 3,500 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $117.86, for a total value of $412,510.00. Following the completion of the sale, the insider now directly owns 33,400 shares in the company, valued at $3,936,524. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Joel S. Goldberg sold 4,000 shares of the stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $110.46, for a total value of $441,840.00. Following the transaction, the insider now directly owns 36,900 shares of the company’s stock, valued at $4,075,974. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joel S. Goldberg sold 3,500 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total value of $412,510.00. Following the completion of the transaction, the insider now directly owns 33,400 shares in the company, valued at $3,936,524. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.
Revvity Company Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Featured Stories
- Five stocks we like better than Revvity
- Short Selling: How to Short a Stock
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 8/26 – 8/30
- What is Put Option Volume?
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTY – Free Report).
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.